Preface. Foreword. 1. Assessing Performance and Setting Targets; T. Eaves. 2. Current Regulatory Reforms and Improvements in the Review Process; F. Sauer. 3. Establishing Performance Targets for the Review Process: The View of the FDA; M. Lumpkin. 4. Current Regulatory Reforms: CBER; K. Zoon. 5. Improving the Review Process: The View of the Japanese MHW; Y. Hirayama. 6. Comparing the Performance of the Canadian Therapeutic Products Directorate with Other Regulatory Authorities; B. Pieterson. 7. Measuring Performance: The View of the TGA; J. McEwen. 8. Why Have Targets for the Review Process? The View of the EMEA; R. Bass. 9. Why Have Targets for the Review Process? The European View of a Pharmaceutical Industry Individual; E. Donnelly. 10. Key Milestones in the Regulatory Review Process? The View of the European Pharmaceutical Industry; K. Thomas. 11. How do You Measure the Quality of the Scientific Assessment and the Process? The View of the MCA; D. Jefferys. 12. Ensuring the Quality of the Scientific Assessment and the Review Process: The FDA's Good Review Practice Initiative; M. Lumpkin. 13. Recommendations for the Syndicate Sessions: Define Mutually Agreeable Measures and Targets for the Review Process for Authorising NMEs and Abridged Applications; V. Silano, et al. 14. Recommendations for Syndicate Sessions: What Are the Appropriate Measures of the Quality of the Review; M. Lumpkin, et al. Index.
"Sinopsis" puede pertenecer a otra edición de este libro.
At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as 'what target should be set for the review of new medicines?' and `how can quality be assured?' are now considered to be of critical importance. The twelfth CMR International Workshop, held in January 1997, provided the opportunity for Regulatory Authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarises the many suggestions that were debated at the Workshop, and includes chapters on measuring performance, and on the integration of quality into the review process.
"Sobre este título" puede pertenecer a otra edición de este libro.
EUR 14,46 gastos de envío desde Reino Unido a España
Destinos, gastos y plazos de envíoEUR 11,00 gastos de envío desde Alemania a España
Destinos, gastos y plazos de envíoLibrería: Fireside Bookshop, Stroud, GLOS, Reino Unido
Cloth/Laminated Boards. Condición: Very Good. Type: Book At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as "what target should be set for the review of new medicines?" and "how can quality be assured?" are now considered to be of critical importance. The 12th CMR International Workshop, held in January 1997, provided the opportunity for regulatory authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarizes the many suggestions that were debated at the workshop, and includes chapters on measuring performance, and on the integration of quality into the review process. 163pp. Nº de ref. del artículo: 015178
Cantidad disponible: 1 disponibles
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as 'what target should be set for the review of new medicines ' and `how can quality be assured ' are now considered to be of critical importance. The twelfth CMR International Workshop, held in January 1997, provided the opportunity for Regulatory Authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarises the many suggestions that were debated at the Workshop, and includes chapters on measuring performance, and on the integration of quality into the review process. 188 pp. Englisch. Nº de ref. del artículo: 9780792387312
Cantidad disponible: 2 disponibles
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: New. In. Nº de ref. del artículo: ria9780792387312_new
Cantidad disponible: Más de 20 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as 'what target should be set for the review of new medicines ' and `how can quality be assured ' are now considered to be of critical importance. The twelfth CMR International Workshop, held in January 1997, provided the opportunity for Regulatory Authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarises the many suggestions that were debated at the Workshop, and includes chapters on measuring performance, and on the integration of quality into the review process. Nº de ref. del artículo: 9780792387312
Cantidad disponible: 2 disponibles
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
Hardback. Condición: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days 526. Nº de ref. del artículo: C9780792387312
Cantidad disponible: Más de 20 disponibles
Librería: moluna, Greven, Alemania
Condición: New. At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiv. Nº de ref. del artículo: 898701330
Cantidad disponible: Más de 20 disponibles
Librería: Revaluation Books, Exeter, Reino Unido
Hardcover. Condición: Brand New. 188 pages. 6.14x0.50x9.21 inches. In Stock. Nº de ref. del artículo: x-0792387317
Cantidad disponible: 2 disponibles